[PDF] Top 20 P-0127MULTIMODALITY TREATMENT APPROACH FOR LOCALLY ADVANCED PANCREATIC CANCER
Has 10000 "P-0127MULTIMODALITY TREATMENT APPROACH FOR LOCALLY ADVANCED PANCREATIC CANCER" found on our website. Below are the top 20 most common "P-0127MULTIMODALITY TREATMENT APPROACH FOR LOCALLY ADVANCED PANCREATIC CANCER".
P-0127MULTIMODALITY TREATMENT APPROACH FOR LOCALLY ADVANCED PANCREATIC CANCER
... Introduction: Pancreatic cancer is the 7th leading cause of cancer-related death worldwide with 5-year survival rates of around ...responsible for the poor outcome even after R0 resection, no ... Voir le document complet
1
Activity of raltitrexed and gemcitabine in advanced pancreatic cancer
... undergoing treatment with the combination gemcitabine plus continuous-infusion 5-FU [3, ...in advanced pancreatic cancer. The recommended dose for capecitabine from this trial was 1300 ... Voir le document complet
6
Therapeutic antibodies for the treatment of pancreatic cancer.: Mabs against pancreatic cancer
... Pancreatic cancer is a devastating disease with the worst mortality rate and an overall 5-year survival rate lower than ...accounting for only 3% of all cancers, this disease is the fourth leading ... Voir le document complet
23
Preclinical Evaluation of Intraoperative Low-Energy Photon Radiotherapy Using Spherical Applicators in Locally Advanced Prostate Cancer
... prostate cancer Introduction Increasing numbers of patients are undergoing surgery for high- risk prostate cancer ( 1 ...with locally advanced prostate adenocarcinoma (stage pT3) will ... Voir le document complet
9
Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
... of treatment mainly because it has been evaluated in only a small number of randomized trials and in a series of small phase II studies, exploring the safety and activity of different platinum ...neoadjuvant ... Voir le document complet
13
Neoadjuvant radiochemotherapy for locally advanced gastric cancer: a phase I-II study
... neoadjuvant treatment program did not seem to increase operative risks ...responsible for this ...operative approach was modified according to the neoadjuvant ... Voir le document complet
6
Liquid Biopsy Approach for Pancreatic Ductal Adenocarcinoma
... Abstract: Pancreatic cancer is a public health problem because of its increasing incidence, the absence of early diagnostic tools, and its ...in pancreatic cancer patients evaluating the ... Voir le document complet
25
2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer
... modality treatment strategies can be envisaged, including induc- tion chemotherapy followed by surgery [22, 59 – 64], induction chemoradiotherapy followed by surgery, or de finitive chemora- diotherapy protocols ... Voir le document complet
16
Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy.: Anti-AXL mAb for pancreatic cancer immunotherapy
... plates for 24h and then switched to serum-free ...mAbs for 1.5h, followed by 200 ng/ml rhGAS6 for 30 ...used for quantifying phosphorylated AXL according to the manufacturer’s ... Voir le document complet
3
Voxel-based identification of local recurrence sub-regions from pre-treatment PET/CT for locally advanced head and neck cancers
... [ 24 ]. This volume closely corresponds to the gross tumor volume (GTV), limiting the use of dose escal- ation strategies. Chaput et al. and Legot et al. [ 25 , 26 ] also investigated the location based on a spatial ... Voir le document complet
12
PROGNOSTIC VALUE OF POSTTREATMENT FEDG-PET IMAGING FOLLOWING COMBINED CHEMORADIATION THERAPY IN LOCALLY ADVANCED CERVICAL CANCER
... posttreatment FEDG-PET to be promising for selecting patients who could be offered completion surgery. It is however impossible to draw any genuine conclusion from this finding as the small number of patients ... Voir le document complet
26
[Combination of anti-EGFR and anti-HER2 antibodies: hope in pancreatic cancer treatment]
... et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403-13 3. Rocha Lima ... Voir le document complet
9
Occupational risk factors for pancreatic cancer in Montreal
... Multisite cancer (MMC) study was to identify occupational circumstances associated with an increased risk of developing some of the most common types of ...justification for performing these analyses now is ... Voir le document complet
117
Designing a broad-spectrum integrative approach for cancer prevention and treatment
... tested for specific mutations to stratify patients to the correct ...personalized treatment approaches can be seen to include a much more comprehensive assessment of genetic and even lifestyle factors, such ... Voir le document complet
68
Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
... (EMEA) for use in combination with paclitaxel as first-line treatment of MBC after showing a benefit of 6 months in PFS in the ECOG 2100 ...breast cancer population was of 1 month in PFS at the cost ... Voir le document complet
6
Targeting MUC4 in pancreatic cancer: miRNAs
... [1-3]. Pancreatic cancer has been the favored model to decipher the cellular mechanisms and the intracellular signaling pathways associated with MUC4 altered ... Voir le document complet
5
Simultaneous neoadjuvant radiochemotherapy with capecitabine and oxaliplatin for locally advanced rectal cancer : Treatment outcome outside clinical trials = Simultane neoadjuvante Radiochemotherapie mit Capecitabin und Oxaliplatin beim lokal fortgeschrittenen Rektumkarzinom : Therapieergebnisse außerhalb klinischer Studien
... oxaliplatin for LARC outside CTR demonstrate similar results as the report- ed phase I and II trials in terms of down- staging and down-sizing, pathological re- gression, sphincter preservation rate, rates of ... Voir le document complet
6
Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer
... (metastatic, locally advanced, or recurrent after surgery) not amenable to curative treatment, (iii) had progressed or were intolerant to L1 with gemcitabine plus platinum (GEMCIS or gemcitabine plus ... Voir le document complet
37
Water Soluble Iron-Based Coordination Trimers as Synergistic Adjuvants for Pancreatic Cancer
... studied for the first ...a pancreatic cancer cell line ...another pancreatic cancer cell line, the combined therapy did not enhance the chemotherapy effect, and the reduction observed ... Voir le document complet
15
ADAM8 as a drug target in pancreatic cancer
... daily for subsequent in vivo ...monitored for 12 days, by which time most of the mice injected with Panc1_A8 cells were moribund and reached endpoint ...Panc1_A8/BK-1361 treatment showed improved ... Voir le document complet
38
Sujets connexes